Vertex enters Duchenne field with $245M buy of Exonics
June 06, 2019 at 18:10 PM EDT
Biotech giant Vertex Pharmaceuticals announced plans Thursday to acquire a Cambridge-based preclinical gene editing startup, giving a run for the money to fellow Cambridge drugmaker Sarepta Therapeutics and others developers of drugs for Duchenne muscular dystrophy.
